Today Johnson & Johnson announced a collaboration between Johnson & Johnson Services, Inc. and a subsidiary of HP Inc. The partnership will be focused on using 3D printing technologies to create better healthcare outcomes at a reduced cost. By working together, the companies plan to combine their scientific, clinical, material science and technological expertise to
Pfizer is reportedly gearing up to test a combination of three cancer drugs in human trials next year. According to the Financial Times, the trial, which will be one of the first to test a trio of immunotherapies, will monitor the safety and efficacy of the combination in patients with solid cancers. Although current immunotherapies
Following weeks of speculation, Teva yesterday made a $40-billion-bid for Mylan NV. Teva has offered $82 per Mylan share in a 50/50 cash/stock transaction valued at just over $40 billion. However, the reaction so far to the news suggests that Teva would need to improve on their bid for it to be accepted. S&P Capital
Johnson & Johnson have announced positive results for the first quarter of 2015, beating earnings expectations. However, the company has been forced to lower their full-year expectations for 2015 from $6.12-$6.27 per share to $6.04-$6.19, as a result of exchange rates with a strong US dollar. The negative currency effect is expected to continue to
Takeda has announced that they have signed a deal with ImmunoGen for two anticancer targets. Takeda signed the agreement with ImmunoGen through its subsidiary Millennium Pharmaceuticals. The agreement, which grants Takeda exclusive rights to use ImmunoGen’s ADC technology for anticancer therapeutics, could be worth up to $230m. Specifically, the Japanese pharmaceutical company has licensed exclusive
Roche has today announced that they have acquired Germany’s Signature Diagnostics. Signature Diagnostics were a privately-held translational oncology and genomics company, based in Potsdam, Germany. The acquisition is the fifth deal that Roche has made within the past year, aimed at building their molecular diagnosis business. Signature Diagnostics focuses on developing large blood plasma and
Roche have today announced their 2014 results, with sales in 2014 growing 1% (5% at constant exchange rates) to 47.46 billion francs. However, net profit for the healthcare company fell 16% to 9.54 billion francs, hit by a one-time restructuring charge. Sales increased 4% (at constant exchange rates) in the Pharmaceuticals Division to 36.7 billion
AstraZeneca have confirmed that they remain confident of generating annual sales of over $45 billion by 2023. The increase is expected as a result of accelerating growth momentum from both AstraZeneca’s existing products and those currently awaiting market approval. Five current growth platforms (diabetes, Brilinta, respiratory, Emerging Markets and Japan) currently account for over half
AstraZeneca has announced that they are acquiring tissue sample specialist, Definiens, increasing their oncology efforts. AstraZeneca’s MedImmune unit is paying an initial $150 million, followed by additional predetermined milestone payments, to acquire Definiens. AstraZeneca noted that Definiens has “pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification
Roche has announced positive Q3 results for 2014, with pharmaceutical sales increasing by 4% in the third quarter to 9.13bn francs, while their diagnostics division grew by 7% to 2.65bn francs. The results were boosted by increased sales of Roche’s new breast cancer drugs, Perjeta and Kadcyla. Sales of Perjeta more than tripled to reach
